Karen M. Anderson
CIK 1762176 · Chief People Officer · last filed 2026-06-24
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
2
Total Filings
38
Lifetime Open-Market Net
-$17.13M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief People Officer | 0 | $40.50 | $0 | -$11.24M | 13 | 2026-06-24 |
| Mimecast Ltd (MIME) Delisted | Chief Human Resources Officer | 8,649 | $79.92 | $691.2K | -$5.89M | 15 | 2022-04-04 |
Recent Filings · Page 2 of 4
38 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-10 | — | Notice (144) | −429 | -$8.1K | EDGAR |
| 2025-02-10 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | — | -$464.8K | EDGAR |
| 2025-02-07 | — | Notice (144) | −30,526 | -$580.8K | EDGAR |
| 2025-02-04 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | −17,203 | -$290.7K | EDGAR |
| 2025-02-03 | — | Notice (144) | −6,471 | -$106.7K | EDGAR |
| 2024-12-17 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | — | -$220.5K | EDGAR |
| 2024-12-13 | — | Notice (144) | −16,500 | -$278.7K | EDGAR |
| 2024-03-26 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | −6,160 | -$430.7K | EDGAR |
| 2024-03-25 | — | Notice (144) | −51,160 | -$624.2K | EDGAR |
| 2024-02-02 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | +23,985 | -$59.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.